Precision BioSciences, Inc.

DTIL

CIK 0001357874 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$34M
↑+5261.1% +$34Mvs FY2024 (Q4)
Operating Income
$13M
Net Income
$12M
Gross Profit
$34M
↑+5261.1% +$34Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Average
48/100
  • Profitability
    0ROIC -55.4% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 13.32 (above 1.5 = solid)
  • Leverage
    82D/E 0.37 (under 0.5 = conservative)
  • Efficiency
    3Asset Turnover 0.24x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +5261.1% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Op Margin -158976.9% · trend -117698.4pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$85K
investment in PP&E
Stock-based comp (TTM)
$10M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$154M
everything owned
Total liabilities
$62M
everything owed
Stockholders' equity
$92M
shareholder claim
Net debt
$-89M
Net cash position ($89M)

Recent performance · 32 quarters

Revenue↑+5261.1% +$34M
$34M
Net Income
$20M
Free Cash Flow↑+80.4% +$78K
$-19K
Operating Margin↓-155283.3pts
-158976.9%

Drill down